Stockpolly
Search
Delisting risk
CMND · NASDAQ · Biotechnology

Clearmind Medicine (CMND)

Develops non-hallucinogenic MEAI treatments for alcohol use disorder and related conditions.

$1.75
Pre-market−0.11 (−6.11%)
At close$1.86(+1.64%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Jul 2023Q4 FY23Oct 2023Q1 FY24Jan 2024Q2 FY24Apr 2024Q3 FY24Jul 2024Q4 FY24Oct 2024Q1 FY25Jan 2025Q2 FY25Apr 2025Q3 FY25Jul 2025Q4 FY25Oct 2025Q1 FY26Jan 2026Q2 FY26Apr 2026
Cost of revenue000000000000
Gross profit000000000000
121112111142
Research & development000000001011
Selling, general & administrative111111111131
Operating income−1—−1−1−1−2−1−1−1−1−4−2
1−200−11010100
Interest income000000000000
Interest expense000000000000
Other non-operating income−1200100−10—00
Income before tax−1−4−1−1−2−1−1−1−1−1−4−2
Income tax expense000000000—00
Net income from continuing operations−1—−1−1−2−1−1−1−1−1−4−2
Net income−1—−1−1−2−1−1−1−1−1−4−2
EPS, basic−$12.86−$45.69−$3.61−$1.12−$2.35−$0.83−$0.95−$0.62−$0.98−$0.48−$3.32−$6.78
EPS, diluted−$12.86−$45.69−$3.61−$1.12−$2.35−$0.83−$0.95−$0.62−$0.98−$0.48−$3.32−$6.78
Weighted average shares, basic000111111110
Weighted average shares, diluted000111111110
EBITDA−1—−1−1−2−1−1—−1−1−4−2
Depreciation & amortization000000000000
EBIT−1−4−1−1−2−1−1−1−1−1−4−2